DE69205566D1 - Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. - Google Patents

Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.

Info

Publication number: DE69205566D1
Authority: DE; Germany
Prior art keywords: enthaelt; impfstoff; hsv; simplex; herpes
Prior art date: 1991-03-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69205566T

Other languages

English (en)

Other versions

DE69205566T3 (de

DE69205566T2 (de

Inventor

Myriam Francotte

Jean-Paul Prieels

Moncef Slaoui

Nathalie Garcon-Johnson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

SmithKline Beecham Biologicals SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-21

Filing date

1992-03-17

Publication date

1995-11-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69205566(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-17 Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA

1995-11-23 Publication of DE69205566D1 publication Critical patent/DE69205566D1/de

1996-04-18 Application granted granted Critical

1996-04-18 Publication of DE69205566T2 publication Critical patent/DE69205566T2/de

2002-09-05 Publication of DE69205566T3 publication Critical patent/DE69205566T3/de

2012-03-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DE69205566T 1991-03-21 1992-03-17 Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. Expired - Lifetime DE69205566T3 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9105992A GB9105992D0 (en)	1991-03-21	1991-03-21	Vaccine
PCT/EP1992/000592 WO1992016231A1 (en)	1991-03-21	1992-03-17	HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A

Publications (3)

Publication Number	Publication Date
DE69205566D1 true DE69205566D1 (en)	1995-11-23
DE69205566T2 DE69205566T2 (de)	1996-04-18
DE69205566T3 DE69205566T3 (de)	2002-09-05

Family

ID=10691946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69205566T Expired - Lifetime DE69205566T3 (de)	1991-03-21	1992-03-17	Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.

Country Status (34)

Country	Link
US (1)	US6027730A (de)
EP (1)	EP0576478B2 (de)
JP (1)	JP3530526B2 (de)
KR (1)	KR100224329B1 (de)
CN (2)	CN1058191C (de)
AP (1)	AP298A (de)
AT (1)	ATE129160T1 (de)
AU (1)	AU650521B2 (de)
BR (1)	BR9205745A (de)
CA (1)	CA2106492C (de)
CY (1)	CY1936A (de)
CZ (1)	CZ280505B6 (de)
DE (1)	DE69205566T3 (de)
DK (1)	DK0576478T4 (de)
ES (1)	ES2081102T5 (de)
FI (1)	FI107881B (de)
GB (1)	GB9105992D0 (de)
GR (1)	GR3017884T3 (de)
HK (1)	HK1004525A1 (de)
HU (1)	HU218025B (de)
IE (1)	IE69560B1 (de)
IL (1)	IL101290A (de)
MA (1)	MA22471A1 (de)
MX (1)	MX9201245A (de)
MY (1)	MY110086A (de)
NO (1)	NO307499B1 (de)
NZ (1)	NZ242057A (de)
PL (1)	PL170059B1 (de)
PT (1)	PT100262B (de)
SA (1)	SA92120459B1 (de)
SK (1)	SK279190B6 (de)
WO (1)	WO1992016231A1 (de)
YU (1)	YU28392A (de)
ZA (1)	ZA922011B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) *	1992-02-12	1992-03-25	Smithkline Beecham Biolog	Vaccines
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
WO1994019013A1 (en) *	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69428136T3 (de) *	1993-03-23	2008-07-10	Smithkline Beecham Biologicals S.A.	3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
WO1994027636A1 (en) *	1993-05-25	1994-12-08	American Cyanamid Company	Adjuvants for vaccines against respiratory syncytial virus
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
CA2209360C (en)	1994-12-28	2010-07-06	University Of Kentucky	Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
US6949244B1 (en)	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en)	1996-04-12	2001-05-22	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en)	1996-04-12	2002-04-11	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en)	1996-12-05	2002-10-22	Quadrant Healthcare (Uk) Limited	Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en)	1997-06-13	2001-08-14	Malaya Chatterjee	Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en)	1997-11-17	2002-03-12	University Of Kentucky Research Foundation	Methods and compositions for the treatment of psoriasis
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
GB9819898D0 (en) *	1998-09-11	1998-11-04	Smithkline Beecham Plc	New vaccine and method of use
CA2773698C (en)	1998-10-16	2015-05-19	Glaxosmithkline Biologicals S.A.	Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US7026155B2 (en)	1999-02-02	2006-04-11	Regents Of The University Of California	Method of reducing bacterial proliferation
EP1104767A1 (de)	1999-11-30	2001-06-06	Stichting Dienst Landbouwkundig Onderzoek	Mono- und Disaccharidederivate die sowohl Fettsäureestern als Sulfatestern enthalten
US9273326B2 (en)	2004-04-30	2016-03-01	The Brigham And Women's Hospital, Inc.	Tetracycline-regulated gene expression in HSV-1 vectors
EP2305296A1 (de)	2004-09-22	2011-04-06	GlaxoSmithKline Biologicals SA	Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
JP2008534467A (ja)	2005-03-23	2008-08-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	組成物
SI2384765T1 (sl)	2005-12-22	2017-03-31	Glaxosmithkline Biologicals S.A.	Streptococcus pneumoniae vakcina
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
MX337528B (es)	2006-03-30	2016-03-09	Glaxosmithkline Biolog Sa	Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
JP5639760B2 (ja)	2006-07-17	2014-12-10	グラクソスミスクラインバイオロジカルズソシエテアノニム	インフルエンザワクチン
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
EP2468300B1 (de)	2006-09-26	2017-12-20	Infectious Disease Research Institute	Impfstoffzusammensetzung mit einem synthetischen Adjuvans
TW200908994A (en)	2007-04-20	2009-03-01	Glaxosmithkline Biolog Sa	Vaccine
MX2009013949A (es)	2007-06-26	2010-05-24	Glaxosmithkline Biolog Sa	Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
CN102458463B (zh)	2009-05-22	2017-01-18	健诺西生物科学公司	针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
MX2011012836A (es)	2009-06-05	2012-04-20	Infectious Disease Res Inst	Adyuvantes sinteticos de glucopiranosil-lipido.
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
RS54933B1 (sr) *	2009-12-21	2016-10-31	Brigham & Womens Hospital Inc	Vakcine herpes simpleks virusa
WO2012074881A2 (en)	2010-11-24	2012-06-07	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US9821054B2 (en) *	2011-03-11	2017-11-21	Turnstone Limited Partnership	Method of vaccination comprising a histone deacetylase inhibitor
CA2832307A1 (en)	2011-04-08	2012-10-18	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3329936A1 (de)	2011-08-22	2018-06-06	Nanobio Corporation	Impfstoff gegen den herpes-simplex-virus als nanoemulsion
US9624273B2 (en)	2011-11-23	2017-04-18	Genocea Biosciences, Inc.	Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
LT2850431T (lt)	2012-05-16	2018-06-25	Immune Design Corp.	Vakcinos, skirtos hsv-2
EP2941269B1 (de)	2013-01-07	2020-12-09	Mucosal Vaccine Technologies LLC	Therapeutische impfstoffe zur behandlung von herpes-simplex-virus-typ 2-infektionen
AU2014253791B2 (en)	2013-04-18	2019-05-02	Immune Design Corp.	GLA monotherapy for use in cancer treatment
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
EP3519427A4 (de)	2016-09-28	2020-03-11	Genocea Biosciences Inc.	Verfahren und zusammensetzungen zur behandlung von herpes
WO2019152821A1 (en)	2018-02-05	2019-08-08	The Brigham And Women's Hospital, Inc.	Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
WO2022152939A1 (en)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4372945A (en) *	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en) *	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) *	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US5149660A (en) *	1982-02-18	1992-09-22	University Patents, Inc.	Diagnostic reagents relating to herpes simplex virus
US4762708A (en) *	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
NZ209308A (en) *	1983-08-30	1991-08-27	Genentech Inc	Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
EP0289550B1 (de) *	1986-10-20	1996-04-10	Chiron Corporation	Impfstoff zur behandlung von hsv
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
NZ230424A (en) *	1988-08-25	1992-05-26	Liposome Co Inc	Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) *	1988-10-27	1999-10-04	リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ	Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) *	1989-05-04	1997-01-28	Igen, Inc.	Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) *	1989-07-21	1992-10-27	Wisconsin Alumni Research Foundation	Method of stimulating the immune systems of animals and compositions useful therefor
AU651949B2 (en) *	1989-07-14	1994-08-11	American Cyanamid Company	Cytokine and hormone carriers for conjugate vaccines
CA2088246A1 (en) *	1990-08-01	1992-02-02	Dennis J. O'callaghan	Gene encoding equine herpesvirus type i glycoprotein d, its gene product, antibodies and their uses
DK0541692T3 (da) *	1990-08-02	1999-11-01	Chiron Corp	Herpes simplex virus VP-16-vacciner
GB9106048D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccines
US5166173A (en) *	1991-01-29	1992-11-24	Genelabs Incorporated	Method of treating herpes simplex virus infection
US5196452A (en) *	1991-01-29	1993-03-23	Genelabs Incorporated	Macrocyclic anti-viral compound and method
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
KR100278157B1 (ko) *	1992-06-25	2001-01-15	장 스테판느	보조약을 함유하는 백신 조성물
WO1994019013A1 (en) *	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69428136T3 (de) *	1993-03-23	2008-07-10	Smithkline Beecham Biologicals S.A.	3-0-Deazylierte Monophosphoryl Lipid A enthaltende Impfstoff-Zusammensetzungen
WO1994027636A1 (en) *	1993-05-25	1994-12-08	American Cyanamid Company	Adjuvants for vaccines against respiratory syncytial virus

1991
- 1991-03-21 GB GB9105992A patent/GB9105992D0/en active Pending
1992
- 1992-03-17 AU AU13657/92A patent/AU650521B2/en not_active Expired
- 1992-03-17 DE DE69205566T patent/DE69205566T3/de not_active Expired - Lifetime
- 1992-03-17 CA CA 2106492 patent/CA2106492C/en not_active Expired - Lifetime
- 1992-03-17 KR KR1019930702835A patent/KR100224329B1/ko not_active IP Right Cessation
- 1992-03-17 WO PCT/EP1992/000592 patent/WO1992016231A1/en active IP Right Grant
- 1992-03-17 PL PL92300617A patent/PL170059B1/pl unknown
- 1992-03-17 HU HU9302645A patent/HU218025B/hu unknown
- 1992-03-17 ES ES92906441T patent/ES2081102T5/es not_active Expired - Lifetime
- 1992-03-17 EP EP19920906441 patent/EP0576478B2/de not_active Expired - Lifetime
- 1992-03-17 BR BR9205745A patent/BR9205745A/pt not_active Application Discontinuation
- 1992-03-17 CZ CS931958A patent/CZ280505B6/cs not_active IP Right Cessation
- 1992-03-17 AT AT92906441T patent/ATE129160T1/de active
- 1992-03-17 CY CY193692A patent/CY1936A/xx unknown
- 1992-03-17 SK SK946-93A patent/SK279190B6/sk unknown
- 1992-03-17 JP JP50598492A patent/JP3530526B2/ja not_active Expired - Lifetime
- 1992-03-17 DK DK92906441T patent/DK0576478T4/da active
- 1992-03-18 MY MYPI92000448A patent/MY110086A/en unknown
- 1992-03-19 PT PT100262A patent/PT100262B/pt not_active IP Right Cessation
- 1992-03-19 IE IE920881A patent/IE69560B1/en not_active IP Right Cessation
- 1992-03-19 NZ NZ242057A patent/NZ242057A/en not_active IP Right Cessation
- 1992-03-19 CN CN92102950A patent/CN1058191C/zh not_active Expired - Lifetime
- 1992-03-19 IL IL10129092A patent/IL101290A/en not_active IP Right Cessation
- 1992-03-19 ZA ZA922011A patent/ZA922011B/xx unknown
- 1992-03-19 MA MA22760A patent/MA22471A1/fr unknown
- 1992-03-20 MX MX9201245A patent/MX9201245A/es unknown
- 1992-03-20 AP APAP/P/1992/000368A patent/AP298A/en active
- 1992-03-20 YU YU28392A patent/YU28392A/sh unknown
- 1992-04-21 SA SA92120459A patent/SA92120459B1/ar unknown
1993
- 1993-09-20 NO NO933343A patent/NO307499B1/no not_active IP Right Cessation
- 1993-09-21 FI FI934134A patent/FI107881B/fi not_active IP Right Cessation
1994
- 1994-09-09 US US08/303,542 patent/US6027730A/en not_active Expired - Lifetime
1995
- 1995-10-25 GR GR950402992T patent/GR3017884T3/el unknown
1998
- 1998-01-05 CN CN98103933A patent/CN1101226C/zh not_active Expired - Lifetime
- 1998-04-28 HK HK98103623A patent/HK1004525A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
CN1201692A (zh)	1998-12-16
EP0576478B2 (de)	2001-04-18
DK0576478T3 (da)	1995-12-04
CZ280505B6 (cs)	1996-02-14
DK0576478T4 (da)	2001-07-23
MX9201245A (es)	1992-10-01
PL170059B1 (pl)	1996-10-31
CA2106492C (en)	2003-12-09
KR100224329B1 (ko)	1999-10-15
DE69205566T3 (de)	2002-09-05
FI934134A (fi)	1993-09-21
NO933343D0 (no)	1993-09-20
IL101290A (en)	1996-07-23
CN1101226C (zh)	2003-02-12
MA22471A1 (fr)	1992-10-01
US6027730A (en)	2000-02-22
EP0576478A1 (de)	1994-01-05
SK279190B6 (sk)	1998-07-08
ES2081102T3 (es)	1996-02-16
ES2081102T5 (es)	2001-09-01
AP9200368A0 (en)	1992-04-30
FI107881B (fi)	2001-10-31
ATE129160T1 (de)	1995-11-15
CY1936A (en)	1992-03-17
NZ242057A (en)	1993-12-23
HUT67052A (en)	1995-01-30
AP298A (en)	1994-01-14
JP3530526B2 (ja)	2004-05-24
MY110086A (en)	1997-12-31
CZ195893A3 (en)	1994-07-13
HK1004525A1 (en)	1998-11-27
SK94693A3 (en)	1994-05-11
IE69560B1 (en)	1996-10-02
HU218025B (hu)	2000-05-28
CA2106492A1 (en)	1992-09-22
ZA922011B (en)	1993-01-27
PT100262B (pt)	2001-05-31
BR9205745A (pt)	1994-10-18
SA92120459B1 (ar)	2005-06-14
PT100262A (pt)	1993-06-30
EP0576478B1 (de)	1995-10-18
GR3017884T3 (en)	1996-01-31
YU28392A (sh)	1994-11-15
AU650521B2 (en)	1994-06-23
IE920881A1 (en)	1992-09-23
WO1992016231A1 (en)	1992-10-01
GB9105992D0 (en)	1991-05-08
CN1058191C (zh)	2000-11-08
FI934134A0 (fi)	1993-09-21
CN1065997A (zh)	1992-11-11
IL101290A0 (en)	1992-11-15
DE69205566T2 (de)	1996-04-18
JPH06505727A (ja)	1994-06-30
NO307499B1 (no)	2000-04-17
AU1365792A (en)	1992-10-21
NO933343L (no)	1993-09-20
HU9302645D0 (en)	1994-01-28

Publication	Publication Date	Title
DE69205566D1 (en)	1995-11-23	Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.
ZA926733B (en)	1993-03-10	1,2-Dihydro-2-oxopyridines.
DE69107059D1 (en)	1995-03-09	Sigma-delta-modulator.
GR3022463T3 (en)	1997-04-30	1-H-3-aryl-pyrrolidin-2,4-dion-derivatives
ZA92908B (en)	1993-08-09	Compounds.
AR244753A1 (es)	1993-11-30	Azocolorantes.
DE58908138D1 (en)	1994-09-08	2,3-difluorbenzole.
HU9302708D0 (en)	1994-01-28	Double-string, ring oligonucleotids
DE58905134D1 (en)	1993-09-09	2,3-difluorbiphenyle.
DE69104185D1 (en)	1994-10-27	Luftreservoir.
DE69112211D1 (en)	1995-09-21	Luftreinigungsvorrichtung.
DE69111595D1 (en)	1995-08-31	Squarylium- und crokonyliumfarbstoffe.
ZA929517B (en)	1993-07-12	Compounds.
DE59204008D1 (en)	1995-11-16	Trachealstent.
ZA926482B (en)	1993-03-08	Cyanophenylpyrroles.
DE69106281D1 (en)	1995-02-09	Phenanthrenderivat.
ZA927792B (en)	1993-04-20	Anti-alpha6-integrin-antibodies.
ZA929590B (en)	1994-06-10	Diphenylsulphides.
DE69102644D1 (en)	1994-07-28	Demodulationsreferenzsignalquelle.
OA09716A (en)	1993-08-30	Benzoxaiole derivatives.
DE68913498D1 (en)	1994-04-07	1,1-dioxo-cephem-4-carbothiolsäure-derivate.
DE69114491D1 (en)	1995-12-14	Olefincopolymere.
DE69110012D1 (en)	1995-06-29	Linienerkennungsverfahren.
DE69205795D1 (en)	1995-12-07	Mesoprotheseunterlage.
EP0572573A4 (de)	1994-10-12	Aus schilddrüsen gewonnener chondrozyten-stimulierender faktor.

Legal Events

Date	Code	Title
1996-10-17	8363	Opposition against the patent
2001-06-21	8366	Restricted maintained after opposition proceedings
2001-10-25	8332	No legal effect for de